This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sage, P. R. Articles by Horowitz, J. D. Search for Related Content PubMed PubMed Citation Articles by Sage, P. R. Articles by Horowitz, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE NITROGLYCERIN Related Collections Cardiovascular Pharmacology

(Circulation. 2000;102:2810.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Nitroglycerin Tolerance in Human Vessels

Evidence for Impaired Nitroglycerin Bioconversion

Presented in part at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Ga, November 7–10, 1999, and published in abstract form (Circulation. 1999;100:I-186).

Peter R. Sage, MBBS, FRACP; Ivan S. de la Lande, DSc; Irene Stafford, BSc; Catherine L. Bennett, BSc (Hons); George Phillipov, PhD; John Stubberfield, MBBS, FRACS; John D. Horowitz, MBBS, PhD

From the Departments of Cardiology (P.R.S., I.S.d.l.L., I.S., C.L.B., J.D.H.) and Endocrinology (G.P.), The Queen Elizabeth Hospital, North Western Adelaide Health Service, University of Adelaide, and Department of Cardiothoracic Surgery (J.S.), Royal Adelaide Hospital, Adelaide, Australia.

Correspondence to Prof John Horowitz, Dept of Cardiology, TQEH Campus, NWAHS, Woodville Rd, Woodville, South Australia 5011, Australia. E-mail john.horowitz{at}adelaide.edu.au

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—The basis for progressive attenuation of the effects of organic nitrates during long-term therapy (nitrate tolerance) remains controversial; proposed mechanisms include impaired nitrate bioconversion resulting in decreased release of nitric oxide (NO) from nitrates and/or increased NO clearance through a reaction with incrementally generated superoxide (O₂^–).

Methods and Results—Patients undergoing elective coronary artery bypass were randomized to receive 24 hours of intravenously infused nitroglycerin (NTG; nitrate group) or no nitrate therapy (control group). Discarded segments of the internal mammary artery and saphenous vein were used to examine (1) vascular responsiveness to NTG, sodium nitroprusside, and the calcium ionophore A23187; (2) bioconversion of NTG to 1,2- and 1,3-glyceryl dinitrate; and (3) the generation of O₂^–. Responses to NTG were reduced 3- to 5-fold in vessels from the nitrate group compared with control vessels (P<0.01 for both types of segments), whereas responses to sodium nitroprusside and A23187 were unchanged. Tissue content of 1,2-glyceryl dinitrate was lower (P=0.012) in the saphenous veins from the nitrate group than in those from the control group. O₂^– generation was greater (P<0.01) in internal mammary artery samples from the nitrate group than in those from the control group. However, incremental O₂^– generation induced by an inhibitor of superoxide dismutase did not affect NTG responses.

Conclusions—NTG tolerance in patients with coronary artery disease is nitrate-specific and is associated with evidence of impaired NTG bioconversion. Tolerance was associated with incremental O₂^– generation, but short-term elevation of O₂^– did not affect NTG responsiveness, suggesting increased NO clearance by O₂^– has a minimal contribution to tolerance.

Key Words: nitroglycerin • nitrate tolerance • superoxide

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Long-term therapy with most, if not all, organic nitrates is frequently associated with a progressive reduction of hemodynamic and antiaggregatory effects (a phenomenon termed nitrate tolerance).^{1 2} This imposes the major limitation of efficacy on nitrate therapy for stable angina pectoris, congestive heart failure, and acute myocardial infarction. This attenuation of hemodynamic effects may be due in part to neurohumoral mechanisms opposing nitric oxide (NO)-mediated vascular relaxation³ (pseudotolerance) and in part to a diminished NO effect^{4 5} (true tolerance). The mechanism(s) responsible for true tolerance remain controversial. Multiple theories have been proposed,⁶ but the major categories are (1) impaired nitrate bioconversion resulting in diminished NO release^{5 7} and (2) increased NO clearance mediated by the incremental generation of superoxide (O₂^–).⁸ The supporting evidence for these mechanisms has been derived almost entirely from animal studies; definitive evidence from studies in human subjects is lacking.

We now report an investigation of possible mechanisms of the induction of true tolerance to nitroglycerin (NTG) in human vessels, with an assessment of the following: (1) the extent of cross-tolerance between NTG and non-nitrate sources of NO, (2) changes in the nitrate bioconversion process associated with tolerance induction, and (3) the possible augmented generation of vascular O₂^– and its relationship with vascular responsiveness to NTG.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patient Selection
The investigation was a randomized study of potential in vivo nitrate tolerance induction in patients awaiting elective coronary bypass surgery for mild to moderate angina. Exclusion criteria were concomitant therapy with sulfhydryl-containing medications (eg, captopril, gold salts, and penicillamine), previous adverse effects of organic nitrates, vitamin supplement ingestion, and/or the presence of hemodynamically significant valvular heart disease.

The study was approved by the Ethics Committees of both hospitals. All patients involved in the study gave informed consent.

Experimental Protocol
Patients were randomized to receive either no nitrate therapy (control group) or 10 µg/min NTG as an intravenous infusion via nonadsorptive tubing (nitrate group) for 24 hours before surgery. All other prophylactic antianginal agents were continued unchanged, as summarized in Table 1; in all cases, aspirin had been withdrawn >7 days before the study. Patients were withdrawn from the study if angina recurred in the 24-hour study period, if significant hypotension (systolic blood pressure <90 mm Hg) or a headache unresponsive to paracetamol occurred, or if surgery was postponed for other reasons. NTG infusion was continued unchanged throughout the operation. During the operation, the discarded segments of the distal left internal mammary artery (IMA) and/or proximal saphenous vein (SV) were collected. The vessels were placed in ice-cold Krebs solution, cleaned, and cut into 2- to 3-mm segments.

View this table: [in this window] [in a new window]   Table 1. Patient Characteristics

Vascular Reactivity Studies
Segments were suspended under tension in 15-mL organ baths containing Krebs solution at 37°C. IMA segment resting tension was normalized for internal diameter, as previously described.⁹ Mean resting tension was 2.03 g and 2.04 g for control and tolerant IMA segments, respectively. SV segment resting tension was set at 1 g because this tension gave optimal contractions to KCl solution (120 mmol/L) in preliminary experiments. The segments were equilibrated for 60 minutes before exposure to KCl solution; segments contracting <1 g were discarded. After a further 30 minutes of washout, the segments were contracted with increasing concentrations of norepinephrine (0.01 to 10 µmol/L).

Preliminary studies had revealed that blocking ß-adrenoceptors and catecholamine uptake with 10 µmol/L propranolol and 30 nmol/L desipramine, respectively, potentiated responses to norepinephrine in SV but not IMA segments; these agents were routinely added to SV segments 15 minutes before exposure to norepinephrine. After a further 45 minutes of washout, the segments were preconstricted with norepinephrine to produce 70% of maximum tension in the IMA (1.1±0.1 µmol/L in both groups) and 50% of maximum tension in the SV (0.4±0.1 µmol/L in both groups). Once the contractile response had reached a plateau, each segment was exposed to increasing concentrations of NTG (0.001 to 10 µmol/L and 0.01 to 10 µmol/L for IMA and SV segments, respectively), sodium nitroprusside (SNP; 0.001 to 10 µmol/L and 0.01 to 10 µmol/L for IMA and SV segments, respectively), or the calcium ionophore A23187 (0.01 to 3 µmol/L for both IMA and SV). All segments were then assessed for endothelium-dependent relaxation; segments unresponsive to A23187 were not used for analysis. Time from harvest of vessels to assessment of relaxant responses was held constant at 3 hours and 15 minutes.

NTG Bioconversion Studies
NTG bioconversion studies were conducted only in SV segments because of limited tissue availability. Segments were weighed and equilibrated in Krebs at 37°C. At 3 hours after harvest, 1 segment was placed into 1 mL of Krebs at 37°C and incubated with 1 µmol/L NTG (final concentration) for 2 minutes. The segment was then rinsed for 5 s in ice-cold Krebs before snap-freezing in liquid nitrogen. A control segment was incubated with NTG vehicle but otherwise treated identically. SV segments were stored at -80°C until assay.

NTG and its dinitrate metabolites (1,2- and 1,3-glyceryl dinitrate [GDN]) were extracted from SV segments using a modification of the 2-step extraction procedure of Bennett et al.¹⁰ Frozen SV segments were placed in glass extraction tubes containing internal standard (1,4-dinitrooxy-butan-2-ol) and extracted twice with 5 mL of hexane to selectively isolate the NTG; hexane extracts were then combined. The SV was then extracted with 5 mL of methyl tert-butyl ether containing the internal standard to isolate the 1,2- and 1,3-GDN. Organic phases were dried with anhydrous sodium sulfate, concentrated to 200 µL under a stream of nitrogen, and stored at -20°C until assay. Standard curves were prepared by spiking 1 mL of Krebs with NTG (1 to 50 pmol), 1,2-GDN (0.4 to 10 pmol), and 1,3-GDN (0.1 to 5 pmol) and extracted as for SV.

NTG, 1,2-GDN, and 1,3-GDN were separated using a Varian 3300 gas chromatograph with an electron capture detector and a BP-1 (100% dimethyl polysiloxane) capillary column (25 mx0.53 m internal diameter; 1 µm of film) from SGE. Column temperature was programmed at 125°C; this was followed by thermal cleaning between each 1-µL injection. The injector temperature was 125°C, and the detector temperature was 250°C. Hydrogen was the carrier gas (4 mL/minute), and nitrogen was the makeup gas (20 mL/minute). Under these conditions, the retention times for NTG, 1,2-GDN, 1,3-GDN, and the internal standard were 6.2, 6.5, 7.9, and 9.3 minutes, respectively. Peak height ratios for NTG, 1,2-GDN, and 1,3-GDN to internal standard were used for quantitation. The intra-assay coefficient of variation was 11% (n=5) for NTG, 1,2-GDN, and 1,3-GDN at concentrations of 1, 0.4, and 0.1 pmol, respectively, and the interassay assay coefficient of variation was <10% (n=9) at concentrations of 20, 4, and 2 pmol, respectively.

O₂^– Generation
O₂^– generation studies were performed only in IMA segments because preliminary investigations revealed a greater variability within control SV segments (mean±SEM, 48±10 counts · min^–1 · mg^–1; n=10) than in IMA segments (mean±SEM, 32±4 counts · min^-1 · mg^-1; n=10) for luminescence counts. Further patients (n=21) were randomized as described above, and IMA segments were obtained during the operation to determine O₂^– generation via lucigenin-enhanced chemiluminescence, as described by Ohara et al.¹¹ The segment was first equilibrated in Krebs solution at 37°C and then equilibrated in Krebs-HEPES buffer at 37°C for 30 minutes. It was then placed in 0.5 mL of Krebs-HEPES buffer containing 250 µmol/L lucigenin at 37°C in a Picolite luminometer (Packard), and luminescence counts were measured every minute for 15 minutes. The segments were then weighed. Background counts were determined for 15 minutes before adding the segment; they were then subtracted from the luminescence counts, and the results are expressed as count · min^–1 · mg^–1. Results reported are the mean for 2 segments from each patient measured at 90 and 120 minutes after harvest. High concentrations of lucigenin were recently shown to contribute to O₂^– generation via redox cycling¹² ; to exclude distortion of the results due to this artifactual generation, a limited number of additional experiments were also performed using 10 µmol/L lucigenin.

Effects of Increased O₂^– Generation
The effect of inhibiting endogenous superoxide dismutase with diethyldithiocarbamic acid (DETCA)¹³ on O₂^– generation and relaxant responses to NTG was studied using IMA segments obtained from nonrandomized patients on no nitrate therapy (n=5). Segments were allocated to study either O₂^– generation or NTG reactivity (performed in simultaneous experiments) in a manner identical to that described above. Before measuring O₂^– generation or determining the relaxant response to NTG, some segments were exposed to 1 mmol/L DETCA for 30 minutes followed by 30 minutes of washout. Other segments were incubated with DETCA vehicle only.

Statistics
Results are expressed as mean±SEM. Vascular relaxant responses were compared using the parameters concentration eliciting half the maximum response (EC₅₀ expressed in log units) and maximum response (E_max) with an unpaired t test. NTG and dinitrate content are expressed in pmol/mg and were compared using an unpaired t test. Lucigenin-enhanced chemiluminescence is expressed as count · min^–1 ·mg^–1 and was compared using an unpaired t test. DETCA studies were analyzed using a paired t test.

Materials
(±)Arterenol bitartrate salt, the calcium ionophore A23187, DETCA, desipramine hydrochloride, HEPES sodium salt, bis-N-methylacridinium nitrate (lucigenin), dl-propranolol hydrochloride, and SNP were purchased from Sigma. NTG was purchased from David Bull Laboratories, and the 1,2-GDN and 1,3-GDN were purchased from Radian International. Hexane was residue-analysis grade and was purchased from Fluka, and the methyl tert-butyl ether was Omnisolv grade and was purchased from EM Science.

The internal standard 1,4-dinitrooxy-butan-2-ol was prepared from 1,4-dibromo-butan-2-ol (Aldrich) by displacing the bromo groups using silver nitrate and subsequently purifying it using silica-gel column chromatography.

The Krebs and Krebs-HEPES solutions were gassed with carbogen (95% O₂ and 5% CO₂) and were of the following compositions (in mmol/L): NaCl 118, KCl 3.89, KH₂PO₄ 1.18, NaHCO₃ 25, MgCl₂ 1.05, CaCl₂ 2.34, EDTA 0.01, and glucose 5.56 for Krebs (pH 7.4) and NaCl 99, KCl 4.69, CaCl₂ 1.87, MgCl₂ 1.20, K₂HPO₄ 1.03, NaHCO₃ 25, Na-HEPES 20, and glucose 11.1 for Krebs-HEPES (pH 7.4).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Patient Characteristics
The clinical characteristics of patients studied in the experiments on vascular reactivity and NTG bioconversion are summarized in Table 1. The groups were well balanced; similar numbers of patients in each group were on ACE inhibitors and nitrates before entry into the study and, at operation, similar numbers of each bypass conduit were used in each group.

Patient characteristics of the subgroup randomized to examine O₂^– generation (n=21) were similar to those of the initial randomized cohort; again, no significant differences existed between control and nitrate groups. Specifically, no disparity existed regarding prior nitrate therapy, ACE inhibitor or statin therapy, or hypercholesterolemia.

Studies of Vascular Reactivity
Vasoconstrictor Responses
Vasoconstrictor responses to either KCl solution or norepinephrine did not differ between segments from the control and nitrate groups (data not shown).

Vasodilator Responses
In both IMA and SV segments, relaxations to NTG, SNP, and A23187 were characterized by sigmoid concentration-response curves.

IMA Segments: Compared with segments from the control group, segments from the nitrate group (1) were less responsive to NTG (Figure 1A), with an 5-fold increase in EC₅₀ and a reduction in E_max from 97% to 85% (Table 2), and (2) did not differ in responsiveness to either SNP or A23187 (Figures 1B and 1C; Table 2).

View larger version (22K): [in this window] [in a new window]   Figure 1. Effect of NTG treatment on responses of IMA (left) and SV (right) to NTG (A), SNP (B), and A23187 (C ). Open symbols indicate control group, and closed symbols, nitrate group. Differences between segments from control and nitrate groups were significant only for responses to NTG.

View this table: [in this window] [in a new window]   Table 2. Reactivity of IMA and SV segments to NTG, SNP, and A23187

SV Segments: Similarly, the SV segments from the nitrate group (1) were less responsive to NTG (Figure 1A), with an 3-fold increase in EC₅₀ and a reduction in E_max from 97% to 84% (Table 2), and (2) did not differ in responsiveness to either SNP or A23187 (Figures 1B and 1C; Table 2).

Comparison of IMA and SV
SV segments were less sensitive than IMA segments to NTG. SV segments were also less responsive than IMA segments to A23187; the maximum relaxation was 79% in IMA segments but only 42% in SV segments (Table 2).

NTG Bioconversion Studies: SV
NTG bioconversion was studied in SV segments from 8 patients in the control group and 7 patients in the nitrate group. Mean segment weight (36±7 versus 37±9 mg) and NTG content (0.54±0.06 versus 0.50±0.07 pmol/mg) were similar in both groups.

Tissue content of 1,2-GDN was much greater than that of 1,3-GDN in both groups (Figure 2). Tissue content of 1,2-GDN was significantly lower in segments from the nitrate group compared with control segments (0.10±0.01 versus 0.16±0.02 pmol/mg; P=0.012), but 1,3-GDN content was similar in both groups (Figure 2).

View larger version (15K): [in this window] [in a new window]   Figure 2. SV content of dinitrate metabolites (1,2-GDN and 1,3-GDN) after incubation of segments from control and nitrate groups with 1.0 µmol/L NTG. *P=0.012 for control group vs nitrate group.

O₂^– Generation: IMA
Chemiluminescence counts using 250 µmol/L lucigenin were 70% greater (P<0.01) in the segments from the nitrate group compared with control segments (Figure 3). With 10 µmol/L lucigenin, chemiluminescence counts were significantly (P<0.02) reduced relative to 250 µmol/L lucigenin, but the proportional difference between the nitrate and control groups remained similar (20±3 versus 9±1 count · min^–1 · mg^–1; n=5 each group, P<0.01).

View larger version (10K): [in this window] [in a new window]   Figure 3. Lucigenin-enhanced chemiluminescence for IMA segments from control and nitrate groups. P<0.01 for control group vs nitrate group.

Effects of Increased O₂^– Generation
Incubation of IMA segments with DETCA resulted in an 3-fold increase in chemiluminescence counts over control segments (P<0.01; Figure 4A). However, relaxation of IMA segments with NTG was unchanged (Figure 4B).

View larger version (13K): [in this window] [in a new window]   Figure 4. Effects of 1 mmol/L DETCA on lucigenin-enhanced chemiluminescence (A) and NTG responses (B) in IMA segments from patients not exposed to nitrates. Open symbols indicate control segments, and closed symbols, DETCA-exposed segments. *P<0.01 for control vs DETCA-exposed segments.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The current study is the first investigation of the relative contribution(s) of impaired nitrate bioconversion and incremental O₂^– generation to the induction of NTG tolerance in human vessels. The results can be summarized as follows. (1) Twenty-four hours of therapy with intravenously infused NTG at 10 µg/min in patients with stable angina induces a moderate degree of tolerance to NTG in both the IMA and SV (5-fold and 3-fold reductions in sensitivity, respectively), which is not accompanied by significant cross-tolerance to 2 non-nitrate sources of NO (SNP or A23187). (2) In the tolerant SV, NTG bioconversion to 1,2-GDN is impaired, but bioconversion to 1,3-GDN is unchanged. (3) Tolerance induction in the IMA is associated with a significant increase in O₂^– generation, as measured by lucigenin-enhanced chemiluminescence. However, increasing O₂^– generation by inhibiting endogenous superoxide dismutase with DETCA has no effect on the relaxation of the IMA by NTG.

Nitrate tolerance in the IMA was previously induced by Du et al⁴ after more prolonged prior nitrate therapy. Boesgaard et al¹⁴ demonstrated attenuation of the NTG effect on venous volume in humans after a 23-hour infusion of NTG at a rate slightly lower than that used in this study, although this may have included some component of pseudotolerance. Ex vivo tolerance to NTG in isolated human SVs has not previously been reported. Thus, an important implication of the present observations is that some induction of true tolerance to NTG is inevitable within 24 hours, even at an infusion dose that is at the lower end of most therapeutic protocols.

The role of impaired bioconversion in tolerance induction has previously been investigated largely by 2 methods, which assess either (1) the extent of cross-tolerance to other NO-mediated vasodilators that do not use the nitrate bioconversion pathway¹⁵ or (2) NTG metabolism.^{7 16} The current study used both methods to determine the contribution of impaired NTG bioconversion to true tolerance in human vessels.

Cross-tolerance to non-nitrate sources of NO has been studied in many in vitro^{7 17 18 19 20 21 22} and in vivo^{5 8 23 24 25 26} animal models of tolerance induction. Most^{7 17 18 19 20 21} in vitro pharmacological studies on isolated vessels have shown minimal cross-tolerance to non-nitrate NO sources. However, the relevance of in vitro studies has been questioned because they exclude some factors that may be of importance to tolerance induction in vivo.³ The data from in vivo animal studies are conflicting. Some studies using isolated vessels^{21 23} or hemodynamic indices^{24 25} have demonstrated that tolerance induction is associated with no cross-tolerance to non-nitrate sources of NO. However, others^{8 26} have reported varying degrees of cross-tolerance. By comparison, cross-tolerance data in humans are limited. Studies examining cross-tolerance using in vivo tolerance induction cannot assess the relative contributions of true tolerance and pseudotolerance.²⁷ To our knowledge, the only previous study on isolated vessels from tolerant subjects⁴ found no cross-tolerance to SNP or acetylcholine. Similarly, ex vivo studies of NTG tolerance induction at the level of platelet aggregation in human subjects showed no cross-tolerance between NTG and SNP.² The lack of significant cross-tolerance to other NO-mediated vasodilators that was found in the current study is therefore in agreement with the few previous analogous human studies.

The current study demonstrates for the first time in humans that true NTG tolerance is associated with an impairment of the enzymatic bioconversion of NTG to 1,2-GDN. NTG is a prodrug that undergoes largely enzymatic bioconversion to yield dinitrates (1,2-GDN or 1,3-GDN) and NO, which is responsible for its pharmacological effects. Evidence from animal studies^{28 29} suggests that the conversion of NTG to 1,2-GDN and NO predominates in vascular tissue, thus representing the mechanism-based pathway responsible for the generation of NO. Consistent with this, we found that levels of 1,2-GDN were much higher than 1,3-GDN in both control and tolerant SV segments exposed to NTG. Animal studies have also demonstrated that NTG to 1,2-GDN bioconversion is impaired in association with tolerance induction in vitro²⁹ or in vivo.^{7 16} Furthermore, nitrate tolerance in intact rabbits is associated with diminished NO generation from organic nitrates but not from 3-morpholino-sydnonimine, a direct NO donor.⁵ The results of the current study demonstrate that a similar process occurs in human vessels in vivo. Together, the lack of cross-tolerance to non-nitrate sources of NO and the impairment of the bioconversion of NTG to 1,2-GDN strongly support the primary role of impaired bioconversion in true tolerance to NTG in human vessels.

An alternative theory proposed recently⁸ is that NTG tolerance involves increased clearance of NO via increased O₂^–, the latter being generated primarily as a result of angiotensin II- induced activation of reduced nicotinamide adenine dinucleotide oxidase.³⁰ Furthermore, incremental O₂^– generation has recently been implicated in the pathogenesis of the de novo phenomenon nitrate resistance.³¹ For this reason, we explored the role of O₂^– with regard to tolerance induction in human vessels. The measurement of lucigenin-enhanced chemiluminescence with both 250 and 10 µmol/L lucigenin suggested that tolerant IMA segments had a greater potential for O₂^– generation than control segments; the difference was similar to that reported previously by Münzel et al⁸ in rabbit aortae. These experiments also confirmed the previous observation in some¹² but not all³² studies that the higher concentration of lucigenin contributes to chemiluminescence via redox cycling.

The findings of intact responses to non-nitrate sources of NO, despite increased O₂^– generation in tolerant vessels, prompted the experiments using DETCA (1 mmol/L). Despite increasing O₂^– generation in the IMA 3-fold, DETCA had no effect on NTG responses. This finding was in conflict with previous studies in bovine coronary arteries¹³ and rabbit aortae.³³ However, both previous studies used a 10-fold higher concentration of DETCA (10 mmol/L). We found the latter concentration inhibited contractile responses, as did Omar et al,¹³ suggesting a more nonspecific impairment of cellular function. Furthermore, other investigators^{34 35} have also reported unchanged NTG responses after short-term elevation of O₂^– concentrations. The results of the experiments with DETCA, together with the absence of cross-tolerance to non-nitrate sources of NO, suggest that increased NO inactivation by O₂^– has a minimal effect.

This study has several limitations. First, we cannot exclude the possibility that mechanisms of tolerance may vary with the extent of tolerance induction. We examined only 1 NTG dosing regimen and induced only a moderate degree of tolerance. The previous animal studies that showed significant cross-tolerance to non-nitrate NO sources have, in general, used higher NTG regimens and reported greater degrees of tolerance.^{8 26} Moreover, in this model, we did not observe any evidence of increased sensitivity to vasoconstrictor agents in the tolerant segments; this phenomenon, which is related to pseudotolerance, may have become manifest with other tolerance-induction regimens.^{4 8 23} Critically, the results do not completely exclude a role for the observed increase in O₂^– generation in tolerance induction; it is possible not only that more prolonged elevation of O₂^– generation might affect NO clearance, but also that nitrate bioconversion might be redox-sensitive.

In summary, tolerance remains the major limitation to the clinical utility of organic nitrates. The results of this study should provide impetus to future investigations using nitrate bioconversion as an index of tolerance induction and should further stimulate attempts to identify the sulfhydryl-dependent enzyme system responsible for the bioconversion of NTG in vascular smooth muscle,³⁶ with the expectation that the acceleration of bioconversion will provide a means to circumvent tolerance.

	Acknowledgments

 
This work was supported by grants from the National Health and Medical Research Council of Australia. Dr Sage is a recipient of a National Heart Foundation of Australia Postgraduate Research Scholarship.

Received June 5, 2000; revision received July 21, 2000; accepted July 28, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Schelling J-L, Lasagna L. A study of cross-tolerance to circulatory effects of organic nitrates. Clin Pharmacol Ther. 1967;8:256–260.[Medline] [Order article via Infotrieve]
   
2. Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol. 1997;80:128–131.[Medline] [Order article via Infotrieve]
   
3. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336–2345.[Abstract/Free Full Text]
   
4. Du ZY, Buxton BF, Woodman OL. Tolerance to glyceryl trinitrate in isolated human internal mammary artery. Thorac Cardiovasc Surg. 1992;104:1280–1284.
   
5. Agvald P, Adding LC, Gustafsson LE, et al. Nitric oxide generation, tachyphylaxis and cross-tachyphylaxis from nitrovasodilators in vivo. Eur J Pharmacol. 1999;385:137–145.[Medline] [Order article via Infotrieve]
   
6. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520–531.[Free Full Text]
   
7. Fung H-L, Poliszczuk R. Nitrosothiols and nitrate tolerance. Z Kardiol. 1986;75(suppl 3):25–27.
   
8. Münzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide production in nitrate tolerance: a novel mechanism underlying nitrate tolerance and cross-tolerance. J Clin Invest. 1995;95:187–194.
   
9. He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein and coronary artery to constrictor and dilator substances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol. 1988;12:12–22.[Medline] [Order article via Infotrieve]
   
10. Bennett BM, McDonald BJ, St James MJ. Hepatic cytochrome P-450-mediated activation of rat aortic guanylyl cyclase by glyceryl trinitrate. J Pharmacol Exp Ther. 1992;261:716–723.[Abstract/Free Full Text]
    
11. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551.
    
12. Li Y, Zhu H, Kuppusamy P, et al. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998;273:2015–2023.[Abstract/Free Full Text]
    
13. Omar HA, Cherry PD, Mortelliti MP, et al. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res. 1991;69:601–608.[Abstract/Free Full Text]
    
14. Boesgaard S, Iversen HK, Wroblewski H, et al. Altered peripheral vasodilator profile of nitroglycerin during long-term infusion of N-acetylcysteine. J Am Coll Cardiol. 1994;23:163–169.[Abstract]
    
15. Henry PJ, Horowitz JD, Louis WJ. Nitroglycerin-induced tolerance affects multiple sites in the organic bioconversion cascade. J Pharmacol Exp Ther. 1989;248:762–768.[Abstract/Free Full Text]
    
16. Torfgård KE, Ahlner J, Axelsson KL, et al. Tissue disposition of glyceryl trinitrate, 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate in tolerant and nontolerant rats. Drug Metab Dispos. 1992;20:553–558.[Abstract]
    
17. Kowaluk EA, Poliszczuk R, Fung H-L. Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin. Eur J Pharmacol. 1987;144:379–383.[Medline] [Order article via Infotrieve]
    
18. Mülsch A, Busse R, Winter I, et al. Endothelium- and sydnonimine-induced responses of native and cultured aortic smooth muscle cells are not impaired by nitroglycerin tolerance. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:568–574.[Medline] [Order article via Infotrieve]
    
19. Henry PJ, Drummer OH, Horowitz JD. S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol. 1989;98:757–766.[Medline] [Order article via Infotrieve]
    
20. Kowaluk EA, Fung H-L. Dissociation of nitrovasodilator-induced relaxation from cyclic GMP levels during in vitro nitrate tolerance. Eur J Pharmacol. 1990;176:91–95.[Medline] [Order article via Infotrieve]
    
21. Du ZY, Dusting GJ, Woodman OL. Effect of tolerance to glyceryl trinitrate on vascular responses in conscious rabbits. Clin Exp Pharmacol Physiol. 1991;18:439–447.[Medline] [Order article via Infotrieve]
    
22. Rapoport RM, Waldman SA, Ginsbug R, et al. Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol. 1987;10:82–89.[Medline] [Order article via Infotrieve]
    
23. De la Lande IS, Stafford I, Horowitz JD. Tolerance induction by transdermal glyceryl trinitrate in rats. Eur J Pharmacol. 1999;374:71–75.[Medline] [Order article via Infotrieve]
    
24. Bauer JA, Fung H-L. Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther. 1991;256:249–254.[Abstract/Free Full Text]
    
25. Shaffer JE, Han B-J, Chern WH, et al. Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits. J Pharmacol Exp Ther. 1992;260:286–293.[Abstract/Free Full Text]
    
26. Laursen JB, Boesgaard S, Poulsen HE, et al. Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo. Cardiovasc Res. 1996;31:814–819.[Medline] [Order article via Infotrieve]
    
27. Sütsch G, Kim JH, Bracht C, et al. Lack of cross-tolerance to short-term linsidomine in fore-arm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. Clin Pharmacol Ther. 1997;62:538–545.[Medline] [Order article via Infotrieve]
    
28. McGuire JJ, Anderson DJ, McDonald BJ, et al. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem Pharmacol. 1998;56:881–893.[Medline] [Order article via Infotrieve]
    
29. Bennett BM, Leitman DC, Schröder H, et al. Relationship between biotransformation of glyceryl trinitrate and cyclic GMP accumulation in various cultured cell lines. J Pharmacol Exp Ther. 1989;250:316–323.[Abstract/Free Full Text]
    
30. Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest. 1996;98:1465–1470.[Medline] [Order article via Infotrieve]
    
31. Chirkov YY, Holmes AS, Chirkova LP, et al. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation. 1999;100:129–134.[Abstract/Free Full Text]
    
32. Berry C, Hamilton CA, Brosnan JM, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;101:2206–2212.[Abstract/Free Full Text]
    
33. Münzel T, Hink U, Yigit H, et al. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol. 1999;127:1224–1230.[Medline] [Order article via Infotrieve]
    
34. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265–9269.[Abstract/Free Full Text]
    
35. Hussain AS, Brien JF, Marks GS, et al. Superoxide does not inhibit glyceryl trinitrate-rabbit aortic strip-mediated relaxation: evidence against a role for nitric oxide itself as the smooth muscle active drug metabolite. Drug Metab Dispos. 1996;24:780–785.[Abstract]
    
36. Seth P, Fung H-L. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol. 1993;46:1481–1486.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				U. Hink, A. Daiber, N. Kayhan, J. Trischler, C. Kraatz, M. Oelze, H. Mollnau, P. Wenzel, C. F. Vahl, K. K. Ho, et al. Oxidative Inhibition of the Mitochondrial Aldehyde Dehydrogenase Promotes Nitroglycerin Tolerance in Human Blood Vessels J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2226 - 2232. [Abstract] [Full Text] [PDF]

				J. D. MacPherson, T. D. Gillespie, H. A. Dunkerley, D. H. Maurice, and B. M. Bennett Inhibition of Phosphodiesterase 5 Selectively Reverses Nitrate Tolerance in the Venous Circulation J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 188 - 195. [Abstract] [Full Text] [PDF]

				T. Munzel, A. Daiber, and A. Mulsch Explaining the Phenomenon of Nitrate Tolerance Circ. Res., September 30, 2005; 97(7): 618 - 628. [Abstract] [Full Text] [PDF]

				I. S. Mackenzie, K. M. Maki-Petaja, C. M. McEniery, Y. P. Bao, S. M. Wallace, J. Cheriyan, S. Monteith, M. J. Brown, and I. B. Wilkinson Aldehyde Dehydrogenase 2 Plays a Role in the Bioactivation of Nitroglycerin in Humans Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1891 - 1895. [Abstract] [Full Text] [PDF]

				Z. Chen, M. W. Foster, J. Zhang, L. Mao, H. A. Rockman, T. Kawamoto, K. Kitagawa, K. I. Nakayama, D. T. Hess, and J. S. Stamler An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation PNAS, August 23, 2005; 102(34): 12159 - 12164. [Abstract] [Full Text] [PDF]

				W. Wei, C.-Q. Yang, A. Furnary, and G.-W. He Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 33 - 40. [Abstract] [Full Text] [PDF]

				U. Elkayam, F. Bitar, M. W. Akhter, S. Khan, S. Patrus, and M. Derakhshani Intravenous Nitroglycerin in the Treatment of Decompensated Heart Failure: Potential Benefits and Limitations Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 227 - 241. [Abstract] [PDF]

				J. DiFabio, Y. Ji, V. Vasiliou, G. R. J. Thatcher, and B. M. Bennett Role of Mitochondrial Aldehyde Dehydrogenase in Nitrate Tolerance Mol. Pharmacol., November 1, 2003; 64(5): 1109 - 1116. [Abstract] [Full Text] [PDF]

				S. Muller, U. Laber, J. Mullenheim, W. Meyer, and G. Kojda Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1994 - 2000. [Abstract] [Full Text] [PDF]

				J. D. Horowitz Amelioration of nitrate tolerance: matching strategies with mechanisms J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2001 - 2003. [Full Text] [PDF]

				K. Yamahara, H. Itoh, T.-H. Chun, Y. Ogawa, J. Yamashita, N. Sawada, Y. Fukunaga, M. Sone, T. Yurugi-Kobayashi, K. Miyashita, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration PNAS, March 18, 2003; 100(6): 3404 - 3409. [Abstract] [Full Text] [PDF]

				S.R. Willoughby, S. Stewart, Y.Y. Chirkov, J.A. Kennedy, A.S. Holmes, and J.D. Horowitz Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide Eur. Heart J., December 2, 2002; 23(24): 1946 - 1954. [Abstract] [PDF]

				T. Gori and J. D. Parker Nitrate Tolerance: A Unifying Hypothesis Circulation, November 5, 2002; 106(19): 2510 - 2513. [Full Text] [PDF]

				T. Csont, C. Csonka, A. Onody, A. Gorbe, L. Dux, R. Schulz, G. F. Baxter, and P. Ferdinandy Nitrate tolerance does not increase production of peroxynitrite in the heart Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H69 - H76. [Abstract] [Full Text] [PDF]

				L. J. Ignarro After 130 years, the molecular mechanism of action of nitroglycerin is revealed PNAS, June 11, 2002; 99(12): 7816 - 7817. [Full Text] [PDF]

				Z. Chen, J. Zhang, and J. S. Stamler From the Cover: Identification of the enzymatic mechanism of nitroglycerin bioactivation PNAS, June 11, 2002; 99(12): 8306 - 8311. [Abstract] [Full Text] [PDF]

				W. Wei, H. S. Floten, and G.-W. He Interaction between vasodilators and vasopressin in internal mammary artery and clinical significance Ann. Thorac. Surg., February 1, 2002; 73(2): 516 - 522. [Abstract] [Full Text] [PDF]

				J. D. Parker and T. Gori Tolerance to the Organic Nitrates: New Ideas, New Mechanisms, Continued Mystery Circulation, November 6, 2001; 104(19): 2263 - 2265. [Full Text] [PDF]

				T. Munzel Does nitroglycerin therapy hit the endothelium? J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1102 - 1105. [Full Text] [PDF]

				S. P. Didion, C. A. Hathaway, and F. M. Faraci Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1697 - H1703. [Abstract] [Full Text] [PDF]